Clare Arnott's Publications

About Clare Arnott's Publications

Co-Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Factors associated with the presence and severity of breast arterial calcification: A deep learning-based assessment using screening mammography

    European Journal of Radiology Artificial Intelligence Date published:

  • Associations of Central Adiposity With Subclinical Coronary Calcification and Disease Progression

    JACC: Advances Date published:

  • Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

    Nature Medicine Date published:

  • Views of Women and Health Care Providers Regarding Type 2 Diabetes Screening and Preventive Strategies Post Gestational Diabetes: An Interview Study

    Women's Health Issues Date published:

  • Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk

    Trials Date published:

  • Current evidence for diagnosis and management of cardiac vasculitis

    Heart Date published:

  • Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition

    Journal of the American Society of Nephrology Date published:

  • A Novel Breast Arterial Calcification Age-Based Percentile Nomogram for the Incremental Prediction of Incidental Cardiovascular Events

    JACC: Cardiovascular Imaging Date published:

  • Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities

    American Journal of Preventive Cardiology Date published:

  • SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m2

    Journal of Cardiac Failure Date published:

  • GLP-1 receptor agonists for obesity: eligibility across 99 countries

    The Lancet Diabetes & Endocrinology Date published:

  • Lifestyle intervention versus usual care for improving cardiovascular risk profile in the first year after hypertensive disorders of pregnancy in Australia (Blood Pressure Postpartum): a randomised controlled trial

    The Lancet Obstetrics, Gynaecology, & Women's Health Date published:

  • Initiators of Semaglutide in General Practice in New South Wales, 2020-2023: A Retrospective Cohort Study

    Heart, Lung and Circulation Date published:

  • Incremental value of DXA -derived fat distribution over anthropometrics for classifying metabolically unhealthy obesity: A population-based analysis

    Diabetes, Obesity and Metabolism Date published:

  • Type 2 diabetes after gestational diabetes, a cross-sectional study- DIVINE - NSW

    Diabetic Medicine Date published:

  • Cardiac Impact of Dapagliflozin in Advanced Chronic Kidney Disease: Rationale and Design of the Renal Lifecycle Trial Cardiac Imaging Sub-studies

    Clinical Kidney Journal Date published: